{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yan F"],"funding":["The science fundation of Beijing Ditan Hospital, Capital Medical University","Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University"],"pagination":["2553-2564"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11309941"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["115(8)"],"pubmed_abstract":["Over 50% of patients with hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) are diagnosed at an advanced stage, which is characterized by immune imbalance between CD8+ T cells and regulatory T (Treg) cells that accelerates disease progression. However, there is no imbalance indicator to predict clinical outcomes. Here, we show that the proportion of CD8+ T cells decreases and Treg cells increases in advanced HBV-HCC patients. During this stage, CD8+ T cells and Treg cells expressed the coinhibitory molecule PD-1 and the costimulatory molecule ICOS, respectively. Additionally, the ratio between PD-1+CD8 and ICOS+Tregs showed significant changes. Patients were further divided into high- and low-ratio groups: PD-1+CD8 and ICOS+Tregs high- (PD-1/ICOS<sup>hi</sup>) and low-ratio ("],"journal":["Cancer science"],"pubmed_title":["Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC."],"pmcid":["PMC11309941"],"funding_grant_id":["CCMU2023ZKYXY017","DTQL-202402"],"pubmed_authors":["Yang Z","Zhang Y","Zeng X","Wang X","Zhu B","Shi K","Zhang Q","Yan F"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.","description":"Over 50% of patients with hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) are diagnosed at an advanced stage, which is characterized by immune imbalance between CD8+ T cells and regulatory T (Treg) cells that accelerates disease progression. However, there is no imbalance indicator to predict clinical outcomes. Here, we show that the proportion of CD8+ T cells decreases and Treg cells increases in advanced HBV-HCC patients. During this stage, CD8+ T cells and Treg cells expressed the coinhibitory molecule PD-1 and the costimulatory molecule ICOS, respectively. Additionally, the ratio between PD-1+CD8 and ICOS+Tregs showed significant changes. Patients were further divided into high- and low-ratio groups: PD-1+CD8 and ICOS+Tregs high- (PD-1/ICOS<sup>hi</sup>) and low-ratio (","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-18T20:09:13.881Z","creation":"2025-04-07T07:59:57.502Z"},"accession":"S-EPMC11309941","cross_references":{"pubmed":["38877825"],"doi":["10.1111/cas.16247"]}}